Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 12 | 2024 | 4774 | 0.300 |
Why?
|
| Endometrial Neoplasms | 3 | 2024 | 1380 | 0.200 |
Why?
|
| Laparoscopy | 3 | 2020 | 1291 | 0.140 |
Why?
|
| CA-125 Antigen | 2 | 2024 | 228 | 0.110 |
Why?
|
| Carcinoma | 4 | 2007 | 2627 | 0.100 |
Why?
|
| Vulvar Neoplasms | 2 | 2007 | 236 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2001 | 896 | 0.100 |
Why?
|
| Patient Satisfaction | 2 | 2008 | 917 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2007 | 1913 | 0.090 |
Why?
|
| Pelvic Exenteration | 2 | 2007 | 112 | 0.080 |
Why?
|
| Genital Neoplasms, Female | 2 | 2008 | 790 | 0.080 |
Why?
|
| Uterine Neoplasms | 2 | 2003 | 580 | 0.070 |
Why?
|
| Pelvic Floor | 1 | 2007 | 44 | 0.070 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2007 | 35 | 0.070 |
Why?
|
| Perineum | 1 | 2007 | 115 | 0.070 |
Why?
|
| Hysteroscopy | 1 | 2007 | 48 | 0.070 |
Why?
|
| Frozen Sections | 2 | 2004 | 118 | 0.070 |
Why?
|
| Taxoids | 2 | 2000 | 1008 | 0.070 |
Why?
|
| Hemostasis, Surgical | 1 | 2006 | 55 | 0.070 |
Why?
|
| Electrocoagulation | 1 | 2006 | 65 | 0.070 |
Why?
|
| Surgical Mesh | 1 | 2007 | 211 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2011 | 748 | 0.060 |
Why?
|
| Granulosa Cell Tumor | 1 | 2005 | 81 | 0.060 |
Why?
|
| Collagen | 1 | 2007 | 737 | 0.060 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2003 | 38 | 0.060 |
Why?
|
| Paclitaxel | 2 | 2001 | 2099 | 0.060 |
Why?
|
| Hysterectomy | 1 | 2007 | 644 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2006 | 437 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 749 | 0.050 |
Why?
|
| Health Status | 1 | 2006 | 627 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2001 | 271 | 0.050 |
Why?
|
| Urinary Diversion | 1 | 2002 | 83 | 0.050 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2004 | 329 | 0.050 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2001 | 58 | 0.050 |
Why?
|
| Female | 24 | 2024 | 148398 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2007 | 881 | 0.050 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2001 | 83 | 0.050 |
Why?
|
| Cystadenocarcinoma | 1 | 2000 | 25 | 0.050 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2001 | 165 | 0.050 |
Why?
|
| Middle Aged | 18 | 2020 | 90004 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2004 | 16593 | 0.040 |
Why?
|
| Aged | 15 | 2020 | 73156 | 0.040 |
Why?
|
| Paget Disease, Extramammary | 1 | 2000 | 54 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2004 | 630 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2004 | 6982 | 0.040 |
Why?
|
| Adult | 16 | 2020 | 81523 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2006 | 1043 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2000 | 134 | 0.040 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2000 | 155 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 4981 | 0.040 |
Why?
|
| Camptothecin | 1 | 2000 | 538 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2000 | 770 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2024 | 1934 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 508 | 0.030 |
Why?
|
| Humans | 24 | 2024 | 270757 | 0.030 |
Why?
|
| Mass Screening | 1 | 2024 | 1553 | 0.030 |
Why?
|
| Radiology | 1 | 2020 | 428 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2004 | 2359 | 0.030 |
Why?
|
| Retrospective Studies | 8 | 2020 | 39670 | 0.030 |
Why?
|
| Ovary | 1 | 1999 | 701 | 0.030 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 1999 | 497 | 0.030 |
Why?
|
| Surgeons | 1 | 2020 | 484 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2001 | 1732 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2000 | 851 | 0.030 |
Why?
|
| Mesna | 2 | 2003 | 67 | 0.030 |
Why?
|
| Quality of Life | 1 | 2006 | 4731 | 0.020 |
Why?
|
| Survival Analysis | 4 | 2007 | 9304 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2007 | 5679 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 5567 | 0.020 |
Why?
|
| Neoplasm Staging | 3 | 2007 | 13976 | 0.020 |
Why?
|
| Ifosfamide | 2 | 2003 | 357 | 0.020 |
Why?
|
| Parity | 1 | 2011 | 135 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 30941 | 0.020 |
Why?
|
| Topotecan | 2 | 2001 | 248 | 0.020 |
Why?
|
| Length of Stay | 2 | 2007 | 2010 | 0.020 |
Why?
|
| Algorithms | 1 | 2020 | 3906 | 0.020 |
Why?
|
| Social Class | 1 | 2011 | 321 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2001 | 10349 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2008 | 14678 | 0.020 |
Why?
|
| Contraceptive Devices, Female | 1 | 2007 | 6 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2007 | 66 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 1566 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2004 | 2049 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2007 | 197 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2008 | 239 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2008 | 423 | 0.020 |
Why?
|
| Nuclear Family | 1 | 2005 | 56 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2007 | 15237 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2006 | 289 | 0.020 |
Why?
|
| Sexuality | 1 | 2004 | 38 | 0.020 |
Why?
|
| Myometrium | 1 | 2004 | 83 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 2006 | 294 | 0.010 |
Why?
|
| Alopecia | 1 | 2004 | 123 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 2 | 2004 | 4067 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2004 | 259 | 0.010 |
Why?
|
| Decision Trees | 1 | 2004 | 179 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 2000 | 3538 | 0.010 |
Why?
|
| Survival Rate | 3 | 2002 | 12516 | 0.010 |
Why?
|
| Equipment Design | 1 | 2007 | 1206 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2011 | 2237 | 0.010 |
Why?
|
| Cancer Care Facilities | 1 | 2008 | 908 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 154 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2004 | 516 | 0.010 |
Why?
|
| Vomiting | 1 | 2004 | 361 | 0.010 |
Why?
|
| Nausea | 1 | 2004 | 540 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2006 | 579 | 0.010 |
Why?
|
| Mothers | 1 | 2005 | 418 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 1076 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2001 | 58 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2003 | 7808 | 0.010 |
Why?
|
| Diphenhydramine | 1 | 2000 | 20 | 0.010 |
Why?
|
| Cimetidine | 1 | 2000 | 29 | 0.010 |
Why?
|
| Sentinel Surveillance | 1 | 2000 | 36 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 451 | 0.010 |
Why?
|
| Injections | 1 | 2001 | 289 | 0.010 |
Why?
|
| Clitoris | 1 | 2000 | 9 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2001 | 228 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2004 | 1018 | 0.010 |
Why?
|
| Filgrastim | 1 | 2000 | 194 | 0.010 |
Why?
|
| Thorax | 1 | 2001 | 230 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 2000 | 121 | 0.010 |
Why?
|
| Platinum Compounds | 1 | 2000 | 127 | 0.010 |
Why?
|
| Bridged-Ring Compounds | 1 | 2000 | 180 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2001 | 685 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 2001 | 9040 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 713 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2000 | 221 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2007 | 33785 | 0.010 |
Why?
|
| Melphalan | 1 | 2001 | 877 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 2940 | 0.010 |
Why?
|
| Fatigue | 1 | 2004 | 1277 | 0.010 |
Why?
|
| Etoposide | 1 | 2000 | 905 | 0.010 |
Why?
|
| Cholesterol | 1 | 2001 | 678 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 8044 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2003 | 1645 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 1437 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 16186 | 0.010 |
Why?
|
| Gynecology | 1 | 1999 | 232 | 0.010 |
Why?
|
| Obstetrics | 1 | 1999 | 229 | 0.010 |
Why?
|
| Cisplatin | 1 | 2003 | 2493 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 13343 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2003 | 2264 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 1506 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 3653 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 4967 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 6829 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2000 | 2364 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 9427 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2000 | 3073 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 5897 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 5834 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2001 | 3231 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2003 | 2648 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 5102 | 0.010 |
Why?
|
| Kidney | 1 | 2002 | 2260 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1999 | 934 | 0.010 |
Why?
|
| Gene Expression | 1 | 2001 | 3679 | 0.010 |
Why?
|
| Cytokines | 1 | 2001 | 2836 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2000 | 5085 | 0.010 |
Why?
|
| Biopsy | 1 | 1999 | 3544 | 0.010 |
Why?
|
| Medical Oncology | 1 | 1999 | 1462 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2000 | 10249 | 0.000 |
Why?
|
| United States | 1 | 2004 | 15978 | 0.000 |
Why?
|
| Apoptosis | 1 | 2001 | 7847 | 0.000 |
Why?
|
| Risk Factors | 1 | 2000 | 17819 | 0.000 |
Why?
|
| Prognosis | 1 | 2000 | 22452 | 0.000 |
Why?
|
| Adolescent | 1 | 1999 | 32515 | 0.000 |
Why?
|
| Child | 1 | 1999 | 30328 | 0.000 |
Why?
|